Immunotherapy in severe asthma

A. Bossios (Stockholm, Sweden), W. Canonica (Milan, Italy), C. Porsbjerg (Copenhagen, Denmark)

Source: ERS webinar 2021: Immunotherapy in severe asthma
Number: 0
Disease area: Airway diseases

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Bossios (Stockholm, Sweden), W. Canonica (Milan, Italy), C. Porsbjerg (Copenhagen, Denmark). Immunotherapy in severe asthma. ERS webinar 2021: Immunotherapy in severe asthma

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Omalizumab, a novel therapy for severe allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 37s
Year: 2001

Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009

Omalizumab in children with severe persistent allergic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010

Refining asthma treatment for mild asthma
Source: Virtual Congress 2020 – Rethinking asthma
Year: 2020


Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017

The ERS/EAACI statement on severe exacerbations of asthma, and how to deal with non-allergic severe asthma
Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma
Year: 2019


Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012


Anti-IgE treatment: An alternative for severe allergic occupational asthma
Source: Annual Congress 2012 - Asthma and COPD at work: what are the effects of exposure and risk factors?
Year: 2012


Immunotherapy prevents the development of asthma in subjects with allergic rhinitis
Source: Eur Respir J 2001; 18: Suppl. 33, 482s
Year: 2001

Difficult to treat asthma
Source: Annual Congress 2006 - Clinical year in review
Year: 2006


Management of difficult-to-treat severe asthma
Source: Eur Respir Mon 2011; 51: 282-296
Year: 2011


Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma
Source: Eur Respir J 2002; 19: 846-852
Year: 2002



Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009


Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype
Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections
Year: 2021



Treatment and outcomes in patients with asthma and allergic rhinitis
Source: Eur Respir J 2005; 26: Suppl. 49, 576s
Year: 2005

IL-33 in patients with severe uncontrolled allergic asthma
Source: International Congress 2017 – "Alarming" immunological patterns in asthma
Year: 2017


Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002



Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015